Clinical Trial Update: An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) [Phase 2, Phase 3]

View source ↗

Summary

Open-label study of JZP-458 (RC-P) in acute lymphoblastic leukemia and lymphoblastic lymphoma completed; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Lymphoblastic Lymphoma

Drugs mentioned

• JZP-458 (RC-P) (JZP-458)

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: Acute Lymphoblastic Leukemia, Lymphoblastic Leukemia | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2023-11-18